Brief, daily exposure to 670nm red light rejuvenates aging retinal cells by improving mitochondrial function. In studies on individuals over 40, this non-invasive therapy restored age-related visual acuity decline by as much as 22%.

Nobel Prize-winning research identified genes (Yamanaka factors) that revert specialized adult cells back into their embryonic, stem-cell state. This discovery proves cellular differentiation and aging are not irreversible, opening the door for regenerative therapies by "rebooting" cells to an earlier state.

Ophthalmology has become a "safe haven" for gene therapy because it mitigates the field's two main challenges: safety and manufacturing. Localized delivery to the immune-privileged eye improves the safety profile, while the thousand-fold lower required doses simplify manufacturing and dramatically improve the cost of goods.

Dr. Aubrey de Grey posits that a "preventative maintenance" approach—repairing accumulated cellular damage—is a more direct and achievable engineering problem than trying to slow the complex metabolic processes that cause the damage in the first place, sidestepping our biological ignorance.

A medical procedure called therapeutic plasma exchange, where a person's plasma is removed and replaced with albumin, shows anti-aging potential. In small placebo-controlled trials, this process led to epigenetic markers indicating that some organs and the body overall looked biologically younger.

Founder Sean Ainsworth intentionally started his pioneering AAV gene therapy in an ocular setting before any Western approvals existed. Because an intravitreal injection uses a very small vector amount, it provided a significant safety advantage and a manageable way to prove the technology before attempting systemic delivery.

The composition of proteins in blood changes so dramatically with age that it can accurately predict a person's age. Crucially, these blood-borne factors are not just passive markers; they actively influence how cells and organs function, acting as a form of internal medicine.

Beyond blood, factors in the cerebrospinal fluid (CSF) of young mice have potent rejuvenating effects. In a challenging experiment, infusing young CSF into old mice for a month regenerated the brain, improved cognitive function, and specifically targeted myelin-producing cells (oligodendrocytes).

CEO Lance Baldo suggests that gene therapy in the eye is uniquely positioned for success. As an encapsulated organ with "immune privilege," the eye reduces risks like hepatotoxicity seen in systemic therapies. This creates a safer environment to generate learnings that can then be applied to advance gene therapies for other organs.